Aphexda Patent Expiration

Aphexda is a drug owned by Ayrmid Pharma Ltd. It is protected by 2 US drug patents filed in 2025 out of which none have expired yet. Aphexda's patents will be open to challenges from 09 September, 2027. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 29, 2041. Details of Aphexda's patents and their expiration are given in the table below.

Filter patents by

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US12257285 Composition of BL-8040
Dec, 2041

(16 years from now)

Active
US12268725 Composition of BL-8040
Dec, 2041

(16 years from now)

Active


FDA has granted several exclusivities to Aphexda. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Aphexda, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Aphexda.

Exclusivity Information

Aphexda holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2030. Details of Aphexda's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 08, 2028
Orphan Drug Exclusivity(ODE-442) Sep 08, 2030

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Aphexda is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Aphexda's family patents as well as insights into ongoing legal events on those patents.

Aphexda's Family Patents


Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Aphexda's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 29, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Aphexda Generics:

There are no approved generic versions for Aphexda as of now.





About Aphexda

Aphexda is a drug owned by Ayrmid Pharma Ltd. Aphexda uses Motixafortide Acetate as an active ingredient. Aphexda was launched by Ayrmid Pharma in 2023.

Approval Date:

Aphexda was approved by FDA for market use on 08 September, 2023.

NCE-1 date:

NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Aphexda is 08 September, 2023, its NCE-1 date is estimated to be 09 September, 2027.

Active Ingredient:

Aphexda uses Motixafortide Acetate as the active ingredient. Check out other Drugs and Companies using Motixafortide Acetate ingredient

Dosage:

Aphexda is available in powder form for subcutaneous use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 62MG BASE/VIAL POWDER Prescription SUBCUTANEOUS